Page 19 - Slide 1

Amgen Bone Health Mentoring Program

Monday, October 15, at 11:30am – 2:30pm ◼ Ruth Chris, Minneapolis, MN

FR0360 A Phase IIb Study of MK-5442 Calcium Sensing
Receptor (CaSR) Antagonist in Bisphosphonate-treated
Patients.
Cosman F, Gilchrist N, McClung M, et al.
Session: Welcome Reception and Plenary Poster Session
◼ Friday, October 12, 05:45 PM - 07:00 PM ◼ Discovery
Hall-Hall B/Minneapolis Convention Center

Results Abstract Information Additional Notes from
Poster/Presentation*
Conclusions ▪ Another study indicated that MK-5442 in a
dose of 15 mg caused hypercalcemia, Updated/Additional
Implications Therefore, this group was discontinued. Data, Key Takeaways
for Canadian
▪ In patients switching over to MK-5442 from
Practice ALN, a dose-dependent pulsatile increase
in PTH was noted, which resulted in
increased P1NP (~125% at 12months for
all MK-5442 doses) and u-NTx (~70%-
100%, dose dependant).

▪ In the spine, spine BMD increased slightly
in the ALN with no change in MK-5442
groups

▪ In the hip, BMD declined in the MK-5442
group with no change in the ALN group.

▪ Except for dose-dependent hypercalcemia
, AEs were similar between groups.

▪ In PMW with prior bisphonate therapy, MK-
5442 as compared to ALN continuation
was associated with a pulsatile increase of
PTH and biomarkers of bone formation
and resorption.

▪ Nevertheless, a decreased BMD response
was noted as compared to ALN
continuation.

Discussion Points, Key Takeaways